As of Feb 12
| +0.50 / +0.69%|
The 31 analysts offering 12-month price forecasts for Novartis have a median target of 93.25, with a high estimate of 127.80 and a low estimate of 78.64. The median estimate represents a +28.27% increase from the last price of 72.70.
The current consensus among 33 polled investment analysts is to Buy stock in Novartis. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.